Formosa Laboratories, Inc. · TWSE:4746
Formosa Laboratories — Investor Presentation (November 2024)
22 slides from Formosa Laboratories's investor presentation, Nov 25, 2024
Slide 1: Nov. 25, 2024 TWSE 4746
Nov. 25, 2024 TWSE 4746 2024/11/25 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by Formosa Laboratories Inc. (“Formosalab”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herei
Slide 3: Agenda
• 2023 & 2024 up-to-Oct Operation Results • Business Strategy • Business Update 2024/11/25 3
Slide 4: Operation Results
Operation Results 2024/11/25 4
Slide 5: Revenues up-to-Oct 2024 YoY 6%
Revenues up-to-Oct 2024 YoY 6% 5,000 6% 4,360 4,000 3,766 3,761 3,551 3,142 3,000 2,000 1,000 - 2021 2022 2023 2023 upto 2024 upto Oct Oct Million NTD 2024/11/25 5
Slide 6: Revenues-2024 up-to Oct YoY 6%
Revenues-2024 up-to Oct YoY 6% Million NTD YoY Polymers 1,364 8% Vit. D Derivatives 569 -19% Respiratory Agents 460 17% CDMO 370 -16% Anticancer 189 -6% Steroids 130 279% Others 679 34% Total 3,761 6% 2024/11/25 6
Slide 7: Product Category
Product Category Polyermers Vit. D Derivatives CDMO Respiratory Agents Anticancers CNS Inflammation Steroids Others 7% 7% 10% 13% 15% 1% 1% 6% 5% 3% 1% 0% 4% 4% 7% 6% 5% 3% 6% 4% 4% 3% 5% 3% 3% 9% 6% 11% 8% 12% 14% 16% 12% 12% 10% 19% 19% 15% 19% 19% 33% 33% 34% 36% 36% 2020 2021 2022 2023 2 0 2 4 U
Slide 8: 2024 up to Q3 Profitability
2024 up to Q3 Profitability EPS NTD 1.75 BV per share NTD 64.43 45% 44.0% 42.3% 39.4% 40% 37.3% 35% 30.5% 30% 25% 22.4% 20% 18.4% 15% 13.8% 10.8% 10% 6.2% 6.4% 5% 2.9% 0% 2021 2022 2023 2024 upto Q3 Gross Margin Operating Margin Net Margin 2024/11/25 8
Slide 9: 2023~2024Q3 Profitability
2023~2024Q3 Profitability 55% 44% 45% 44% 45% 43% 43% 43% 41% 35% 26% 25% 26% 25% 24% 23% 25% 23% 22% 20% 20% 18% 21% 17% 16% 15% 21% 15% 8% 5% 2% 2023Q1 2023Q2 2023Q3 2023Q4 2024Q1 2024Q2 2024Q3 -5% -3% -10% -9% -15% Net Operating Margin Operating Profit Income after Tax Operating Expenses 2024/11/
Slide 10: Business Strategy
Business Strategy 2024/11/25 10
Slide 11: Integrated RD and Manufacturing
Integrated RD and Manufacturing • High quality GMP manufacturing Generic • Stable supply chain management API • Effective output to fulfill customer’s demand • Vertical integration Injectable • Supply from development to commercialization stage • One-stop-shop service from drug CDMO substance to dru
Slide 12: Diversified Alliance to Explore Business Opportunity
Diversified Alliance to Explore Business Opportunity Biologics API ADC Injectable API CDMO ADC ADC CDMO Nano-tech HPAPI Nebulizer 2024/11/25 12
Slide 13: Expand oversee market
Expand oversee market 2024/11/25 13
Slide 14: Key Business
Key Business 2024/11/25 14
Slide 15: API Products
API Products Anti-cancers CNS Agents Anti-inflammatory Immunomodulators &Analgesic Agents MRI Enhancing Steroids Agents Respiratory Agents Vit. D Derivatives Polymeric Drugs Antibiotics 2024/11/25 15
Slide 16: Key API Products
Key API Products • Improve throughput • Expand manufacture capacity • Stable supply chain Highlight • Polymer products stay strong market share. The whole year forecast remains positive. • Respiratory API sales keeps growing on revenue. • Steroid products enter originator’s supply chain and deliver
Slide 17: Comprehensive CDMO Service-One Stop Shop
Comprehensive CDMO Service-One Stop Shop 2024/11/25 17
Slide 18: Comprehensive CDMO Service-One Stop Shop
Comprehensive CDMO Service-One Stop Shop API/DS Labelling/ CMC Injectable Research Packaging/ Development Manufacturing Manufacturing Logistics • Clients includes clinical stages and commercial supply in different territories • Stable CMO supply to originator in Japan, Europe, and US. New projects a
Slide 19: One stop ADC services
Service scope Once stop ADC services • Linker-payload, Bioconjugation, and process development • ADC candidate screening platform • Scale-up manufacturing. ADC-DS new line completes validation. The new line can support upto commercial scale supply • Comprehensive analytic services ADC CDMO highlight
Slide 20: Injectable Plant Status
Injectable Plant Status • Authority inspection is ongoing • Cytotoxic line - TFDA: 2022Q2 completed - FDA: 2024 Passed first FDA on-site GMP inspection held in July 2024. - EMA: Expected 2025Q1/Q2 on-site GMP inspection. • General line - TFDA: 2024/08 completed inspection. Expected to receive certif
Slide 21: Self-development Injectable Products
Self-development Injectable Products Eribulin Injectable (Global market size USD 370 million, US Market USD 130 million, TW market NTD 450 million) Territory Status Taiwan Hospital listing keeps going. Already started deliver. Expected to have first medical center invoice in 2025 Q1/Q2 Turkey Lice
Slide 22: Q&A
LX F@nmosa Q&A 2024/11/25 22
Formosa Laboratories — Investor Presentation (November 2024) on 6ix